This multicenter cohort study finds predictors of bone density improvements in women with osteoporosis, suggesting personalized treatment could be beneficial.
Romosozumab demonstrated high effectiveness in this real-world cohort, with a substantial proportion achieving high-magnitude BMD responses despite extensive prior treatment. Distinct site-specific predictors emerged: bone turnover and age/Z-score for LS, prior femoral fracture for FN.
No takes yet. Share an insight, caveat, or question.
Ghielmetti et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: